Clinical trial
Safety Study of Larazotide Acetate to Treat Celiac Disease.
NCT00386165 · 9 Meters Biopharma, Inc., Industry · Completed
Key facts
| NCT number | NCT00386165 |
|---|---|
| Title | Safety Study of Larazotide Acetate to Treat Celiac Disease. |
| Official title | A Phase Ib, Randomized, Double-Blind, Placebo Controlled Study to Determine the Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Effects of Single Doses of Larazotide Acetate (AT-1001) in Celiac Disease Subjects. |
| Lead sponsor | 9 Meters Biopharma, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Celiac Disease |
| Intervention type | Drug |
| Interventions | larazotide acetate |
| Enrollment | 21 |
| Start date | Nov 29, 2005 |
| Primary completion | Jan 26, 2006 |
| Completion | Jan 26, 2006 |
| First posted | Oct 11, 2006 |
| Last update posted | Sep 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: